Cue Biopharma appoints Lucinda Warren interim CEO; Usman Azam steps down as president, CEO, director effective March 26, 2026

Reuters03-28
<a href="https://laohu8.com/S/CUE">Cue Biopharma</a> appoints Lucinda Warren interim CEO; Usman Azam steps down as president, CEO, director effective March 26, 2026
  • Cue Biopharma appointed Lucinda Warren as interim president and CEO, and she will continue as chief financial and business officer.
  • Usman Azam stepped down as president and CEO and resigned as a director, effective March 26, 2026.
  • Warren has served as Cue Biopharma’s chief financial and business officer since February 2026 and previously was chief business officer from September 2024 to February 2026.
  • Before joining Cue Biopharma, she was vice president of business development for Neuroscience and the Japan region at Johnson & Johnson.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271605PRIMZONEFULLFEED9679940) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment